Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides

Vandana Verma, Bjarne Due Larsen, Wanda Coombs, Xianming Lin, Gaelle Spagnol, Paul L Sorgen, Steven M. Taffet, Mario Delmar

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Gap junction pharmacology is a nascent field. Previous studies have identified molecules that enhance intercellular communication, and may offer potential for innovative antiarrhythmic therapy. However, their specific molecular target(s) and mechanism(s) of action remain unknown. Previously, we identified a 34-aa peptide (RXP-E) that binds the carboxyl terminal domain of C43 (Cx43CT) and prevents cardiac gap junction closure and action potential propagation block. These results supported the feasibility of a peptide-based pharmacology to Cx43, but the structure of the core active element in RXP-E, an essential step for pharmacological development, remained undefined. Here, we used a combination of molecular modeling, surface plasmon resonance, nuclear magnetic resonance and patch-clamp strategies to define, for the first time, a unique ensemble of pharmacophores that bind Cx43CT and prevent closure of Cx43 channels. Two particular molecules are best representatives of this family: a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY. These 2 small compounds offer the first structural platform for the design of Cx43-interacting gap junction openers. Moreover, the structure of these compounds offers an imprint of a region of Cx43CT that is fundamental to gap junction channel function.

Original languageEnglish (US)
Pages (from-to)176-184
Number of pages9
JournalCirculation Research
Volume105
Issue number2
DOIs
StatePublished - Jul 17 2009

Fingerprint

Connexin 43
Gap Junctions
Peptides
Pharmacology
Investigational Therapies
Surface Plasmon Resonance
Action Potentials
Magnetic Resonance Spectroscopy

Keywords

  • Arrhythmias
  • Connexin 43
  • Gap junctions

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides. / Verma, Vandana; Larsen, Bjarne Due; Coombs, Wanda; Lin, Xianming; Spagnol, Gaelle; Sorgen, Paul L; Taffet, Steven M.; Delmar, Mario.

In: Circulation Research, Vol. 105, No. 2, 17.07.2009, p. 176-184.

Research output: Contribution to journalArticle

Verma, V, Larsen, BD, Coombs, W, Lin, X, Spagnol, G, Sorgen, PL, Taffet, SM & Delmar, M 2009, 'Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides', Circulation Research, vol. 105, no. 2, pp. 176-184. https://doi.org/10.1161/CIRCRESAHA.109.200576
Verma, Vandana ; Larsen, Bjarne Due ; Coombs, Wanda ; Lin, Xianming ; Spagnol, Gaelle ; Sorgen, Paul L ; Taffet, Steven M. ; Delmar, Mario. / Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides. In: Circulation Research. 2009 ; Vol. 105, No. 2. pp. 176-184.
@article{c463ee9ecff84db7a12416dddc1e419a,
title = "Novel pharmacophores of connexin43 based on the {"}rxp{"} series of Cx43-binding peptides",
abstract = "Gap junction pharmacology is a nascent field. Previous studies have identified molecules that enhance intercellular communication, and may offer potential for innovative antiarrhythmic therapy. However, their specific molecular target(s) and mechanism(s) of action remain unknown. Previously, we identified a 34-aa peptide (RXP-E) that binds the carboxyl terminal domain of C43 (Cx43CT) and prevents cardiac gap junction closure and action potential propagation block. These results supported the feasibility of a peptide-based pharmacology to Cx43, but the structure of the core active element in RXP-E, an essential step for pharmacological development, remained undefined. Here, we used a combination of molecular modeling, surface plasmon resonance, nuclear magnetic resonance and patch-clamp strategies to define, for the first time, a unique ensemble of pharmacophores that bind Cx43CT and prevent closure of Cx43 channels. Two particular molecules are best representatives of this family: a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY. These 2 small compounds offer the first structural platform for the design of Cx43-interacting gap junction openers. Moreover, the structure of these compounds offers an imprint of a region of Cx43CT that is fundamental to gap junction channel function.",
keywords = "Arrhythmias, Connexin 43, Gap junctions",
author = "Vandana Verma and Larsen, {Bjarne Due} and Wanda Coombs and Xianming Lin and Gaelle Spagnol and Sorgen, {Paul L} and Taffet, {Steven M.} and Mario Delmar",
year = "2009",
month = "7",
day = "17",
doi = "10.1161/CIRCRESAHA.109.200576",
language = "English (US)",
volume = "105",
pages = "176--184",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides

AU - Verma, Vandana

AU - Larsen, Bjarne Due

AU - Coombs, Wanda

AU - Lin, Xianming

AU - Spagnol, Gaelle

AU - Sorgen, Paul L

AU - Taffet, Steven M.

AU - Delmar, Mario

PY - 2009/7/17

Y1 - 2009/7/17

N2 - Gap junction pharmacology is a nascent field. Previous studies have identified molecules that enhance intercellular communication, and may offer potential for innovative antiarrhythmic therapy. However, their specific molecular target(s) and mechanism(s) of action remain unknown. Previously, we identified a 34-aa peptide (RXP-E) that binds the carboxyl terminal domain of C43 (Cx43CT) and prevents cardiac gap junction closure and action potential propagation block. These results supported the feasibility of a peptide-based pharmacology to Cx43, but the structure of the core active element in RXP-E, an essential step for pharmacological development, remained undefined. Here, we used a combination of molecular modeling, surface plasmon resonance, nuclear magnetic resonance and patch-clamp strategies to define, for the first time, a unique ensemble of pharmacophores that bind Cx43CT and prevent closure of Cx43 channels. Two particular molecules are best representatives of this family: a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY. These 2 small compounds offer the first structural platform for the design of Cx43-interacting gap junction openers. Moreover, the structure of these compounds offers an imprint of a region of Cx43CT that is fundamental to gap junction channel function.

AB - Gap junction pharmacology is a nascent field. Previous studies have identified molecules that enhance intercellular communication, and may offer potential for innovative antiarrhythmic therapy. However, their specific molecular target(s) and mechanism(s) of action remain unknown. Previously, we identified a 34-aa peptide (RXP-E) that binds the carboxyl terminal domain of C43 (Cx43CT) and prevents cardiac gap junction closure and action potential propagation block. These results supported the feasibility of a peptide-based pharmacology to Cx43, but the structure of the core active element in RXP-E, an essential step for pharmacological development, remained undefined. Here, we used a combination of molecular modeling, surface plasmon resonance, nuclear magnetic resonance and patch-clamp strategies to define, for the first time, a unique ensemble of pharmacophores that bind Cx43CT and prevent closure of Cx43 channels. Two particular molecules are best representatives of this family: a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY. These 2 small compounds offer the first structural platform for the design of Cx43-interacting gap junction openers. Moreover, the structure of these compounds offers an imprint of a region of Cx43CT that is fundamental to gap junction channel function.

KW - Arrhythmias

KW - Connexin 43

KW - Gap junctions

UR - http://www.scopus.com/inward/record.url?scp=68049107032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049107032&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.109.200576

DO - 10.1161/CIRCRESAHA.109.200576

M3 - Article

VL - 105

SP - 176

EP - 184

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 2

ER -